Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) EBITDA: 2015-2024

Historic EBITDA for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to -$251.2 million.

  • Editas Medicine's EBITDA rose 62.62% to -$24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$198.8 million, marking a year-over-year increase of 12.99%. This contributed to the annual value of -$251.2 million for FY2024, which is 48.45% down from last year.
  • According to the latest figures from FY2024, Editas Medicine's EBITDA is -$251.2 million, which was down 48.45% from -$169.2 million recorded in FY2023.
  • In the past 5 years, Editas Medicine's EBITDA registered a high of -$134.8 million during FY2020, and its lowest value of -$251.2 million during FY2024.
  • Moreover, its 3-year median value for EBITDA was -$225.9 million (2022), whereas its average is -$215.4 million.
  • As far as peak fluctuations go, Editas Medicine's EBITDA climbed by 25.12% in 2023, and later plummeted by 48.45% in 2024.
  • Editas Medicine's EBITDA (Yearly) stood at -$134.8 million in 2020, then crashed by 43.24% to -$193.1 million in 2021, then decreased by 16.98% to -$225.9 million in 2022, then climbed by 25.12% to -$169.2 million in 2023, then crashed by 48.45% to -$251.2 million in 2024.